Erste Asset Management Gmb H Iveric Bio, Inc. Transaction History

Erste Asset Management Gmb H

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 26, 2024	SELL	$0.0 - $39.95 $0 - $2.08 Million	-52,000 Closed	0 $0
Q1 2023 Nov 26, 2024	BUY	$18.67 - $24.56 $771,071 - $1.01 Million	41,300 Added 165.2%	66,300 $1.58 Billion
Q4 2022 Nov 26, 2024	BUY	$17.24 - $23.95 $465,479 - $646,650	27,000 Added 108.0%	52,000 $1.09 Billion
Q3 2022 Nov 26, 2024	BUY	$9.4 - $18.59 $235,000 - $464,750	25,000 New	25,000 $433 Million
Q2 2022 Nov 26, 2024	BUY	$9.12 - $18.9 $227,999 - $472,499	25,000 New	25,000 $242 Million
Q1 2022 Nov 22, 2024	BUY	$12.15 - $16.83 $303,750 - $420,749	25,000 New	25,000 $408 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.